Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILT-123 and Avelumab in Solid Tumor Patients
NCT05222932Phase 1Active, not recruiting
- Sponsor
- TILT Biotherapeutics
- Start
- Mar 2023
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of Ad5/3-E2F-D24 in melanoma and head and neck squamous cell carcinoma (HNSCC), sponsored by TILT Biotherapeutics. Primary endpoints: Adverse Events at 85 days, Abnormal Laboratory Values at 85 days and 2 more. Started Mar 2023; status: active, not recruiting.
02
Drugs
Ad5/3-E2F-D24
03
Conditions
melanomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05222932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05222932.